drugset
drugset / Trial / NCT06874842

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

NCT06874842 ↗

Phase 1 Recruiting 92 enrolled Guangzhou Patronus Biotech Co., Ltd.
RandomizedParallel-groupTriple-blindPrevention

Summary

This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.

Timeline

Start
2025-03-13
Primary completion
2026-02
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LYB004 Vaccine 25 ug Intramuscular
Subject LYB004 Vaccine 50 ug Intramuscular
Comparator VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 50 ug Intramuscular

Indications

herpes zoster